3 SEP 2019


Angelini Pharma launches lurasidone hydrocloride-based Latuda in Spain for the treatment of shizophrenia

During the XXII Spanish National Congress of Psychiatry, held from 26 to 28 September in Bilbao, Angelini Pharma launched Latuda (lurasidone hydrochloride) in Spain for the treatment of schizophrenia, a pathology that affects around 450,000 people in Spain.

Latuda’s introduction to the Spanish market follows its launch in Italy, where the drug has been marketed by Angelini Pharma since 2017. On a global level, it has been prescribed for over 13 million patients since January 2011, when the drug was placed on the market by the Japanese company Sumitomo Dainippon Pharma Co. In less than a decade, it has become the world’s most prescribed branded antipsychotic.

We inform you that Angelini Holding S.p.A. uses cookies (small files saved on your hard disk) to improve your browsing experience on this site. Angelini Holding S.p.A. uses third party cookies that allow third parties to access personal data collected during navigation. By continuing to browse the site, by accessing any area of it or selecting an element of it (for example, an image or a link) you consent to the use of cookies. At the following link you will find our extended information on cookies with a description of the categories present and links to the information of third parties as independent data controllers and you will have the opportunity to decide which cookies to authorize or whether to deny consent to all or only some cookies CONTINUE